Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16273
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGrasso, Carole-
dc.contributor.authorAnaka, Matthew-
dc.contributor.authorHofmann, Oliver-
dc.contributor.authorSompallae, Ramakrishna-
dc.contributor.authorBroadley, Kate-
dc.contributor.authorHide, Winston-
dc.contributor.authorBerridge, Michael V-
dc.contributor.authorCebon, Jonathan S-
dc.contributor.authorBehren, Andreas-
dc.contributor.authorMcConnell, Melanie J-
dc.date2016-09-09-
dc.date.accessioned2016-09-15T06:28:18Z-
dc.date.available2016-09-15T06:28:18Z-
dc.date.issued2016-09-09-
dc.identifier.citationBMC Cancer 2016; 16(1): 726en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16273-
dc.description.abstractBACKGROUND: The heterogeneity and tumourigenicity of metastatic melanoma is attributed to a cancer stem cell model, with CD133 considered to be a cancer stem cell marker in melanoma as well as other tumours, but its role has remained controversial. METHODS: We iteratively sorted CD133+ and CD133- cells from 3 metastatic melanoma cell lines, and observed tumourigenicity and phenotypic characteristics over 7 generations of serial xeno-transplantation in NOD/SCID mice. RESULTS: We demonstrate that iterative sorting is required to make highly pure populations of CD133+ and CD133- cells from metastatic melanoma, and that these two populations have distinct characteristics not related to the cancer stem cell phenotype. In vitro, gene set enrichment analysis indicated CD133+ cells were related to a proliferative phenotype, whereas CD133- cells were of an invasive phenotype. However, in vivo, serial transplantation of CD133+ and CD133- tumours over 7 generations showed that both populations were equally able to initiate and propagate tumours. Despite this, both populations remained phenotypically distinct, with CD133- cells only able to express CD133 in vivo and not in vitro. Loss of CD133 from the surface of a CD133+ cell was observed in vitro and in vivo, however CD133- cells derived from CD133+ retained the CD133+ phenotype, even in the presence of signals from the tumour microenvironment. CONCLUSION: We show for the first time the necessity of iterative sorting to isolate pure marker-positive and marker-negative populations for comparative studies, and present evidence that despite CD133+ and CD133- cells being equally tumourigenic, they display distinct phenotypic differences, suggesting CD133 may define a distinct lineage in melanoma.en_US
dc.subjectAC133 antigenen_US
dc.subjectMelanomaen_US
dc.titleIterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populationsen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBMC Canceren_US
dc.identifier.affiliationLudwig Institute for Cancer Research, Olivia Newton-John Cancer & Wellness Centre, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationHarvard T.H. Chan School of Public Health, Boston, MA, USAen_US
dc.identifier.affiliationHarvard Stem Cell Institute, Holyoke Center, Cambridge, MA, USAen_US
dc.identifier.affiliationSheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UKen_US
dc.identifier.affiliationMalaghan Institute of Medical Research, Wellington, New Zealanden_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27613604en_US
dc.identifier.doi10.1186/s12885-016-2759-2en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherCebon, Jonathan S
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.grantfulltextopen-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Files in This Item:
File Description SizeFormat 
art%3A10.1186%2Fs12885-016-2759-2.pdf3.67 MBAdobe PDFThumbnail
View/Open
Show simple item record

Page view(s)

6
checked on Mar 28, 2024

Download(s)

12
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.